

# EXHIBIT E

# Meet Keystone Heart

Keystone Heart, Ltd. is a medical device company developing and manufacturing cerebral embolic protection (CEP) devices to reduce the risk of stroke, neurocognitive decline and dementia caused by brain emboli associated with cardiovascular procedures.

The company is focused on protecting the brain from emboli to reduce the risk of brain infarcts during TAVR, surgical valve replacement, atrial fibrillation ablation, and other cardiovascular procedures. The TriGuard™ Cerebral Embolic Protection Device and TriGuard™ Atrial Embolic Protection Device product pipelines are designed to help interventional cardiologists and electrophysiologists to preserve brain reserve in patients undergoing these procedures.

Headquartered in Israel, with US operations in Tampa, FL, Keystone Heart is dedicated to advancing patient care through innovative technology and clinical research. The company's management team has extensive experience in the fields of interventional cardiology and medical devices.

Keystone Heart holds and maintains a comprehensive IP portfolio and is ISO certified.



## OUR VISION & MISSION

### Our Vision

Keystone Heart aspires to be the world leader in cerebral embolic protection (CEP) during cardiovascular procedures.

### Our Mission

To develop and manufacture novel devices that protect the brain from emboli to reduce the risk of brain infarcts during transcatheter aortic valve replacement (TAVR), atrial fibrillation ablation (AF ablation), and other structural heart procedures.

Cerebral function is essential to maintaining quality of life. Preserving brain reserve during medical procedures is a key component to procedural success and patient care.

## Management Team

### Chris Richardson

President & Chief Executive Officer

Mr. Richardson has spent his 25-year career taking cardiac startup companies from the clinical trial phase through worldwide commercialization and into acquisition. Prior to joining Keystone Heart, Mr. Richardson was international president and CCO of Direct Flow Medical, a transcatheter aortic valve company, and general manager of Abbott Vascular Structural Heart, a global company focused on percutaneous mitral valve repair, which he joined through its acquisition of Evalve. Mr. Richardson has also held leadership positions at Boston Scientific's Cardiac Rhythm Management business and GSC Management Development at Guidant, Heartport (acquired by Johnson & Johnson) and Devices for Vascular Intervention (acquired by Guidant).

### Amit Ashkenazi

COO & Vice President Research & Development

Mr. Ashkenazi has more than 10 years of experience in research and development of medical devices, mainly in the field of interventional ultrasound guidance and labor progress monitoring. Prior to joining Keystone Heart, Mr. Ashkenazi served as Director of Engineering for Trig Medical Ltd. where he was responsible for the product development and commercialization of guidance systems and disposable products.

### Ron Nitzan, Ph.D.

Vice President Quality and Regulatory Affairs

### M. Pauliina Margolis, M.D., Ph.D.

Vice President & Chief Medical Officer

Dr. Pauliina Margolis joined Keystone Heart as Vice President and Chief Medical Officer 2012. Prior to Keystone Heart, Dr. Margolis served as CMO and VP Scientific Affairs at Volcano Corporation 2001-2012. Formerly, she served as medical consultant to different start-up companies including Transvascular Inc, Point BioMedical, PharmaSonics, American Biosciences, Target Therapeutics, and VasConnect, different Venture Capital firms and larger companies in CA, Silicon Valley, USA. Dr. Margolis has authored over 100 original scientific publications including several reviews and book chapters, holds over 20 patents. Her university lectures and teaching include Human Physiology, Oulu, Finland, Cardiology, Cincinnati, USA and Cardiology Edinburgh, UK. Dr. Margolis did her post-doctoral fellowship in experimental coronary ischemia in the University of Cincinnati, UK, specialty in internal medicine, University of Helsinki, Finland, interventional cardiology training, University of Edinburgh, UK, and Early Business Development and Executive Management at Stanford Business School, Stanford University, CA, USA.

### Steve Sandweg

Vice President Sales & Market Development

Mr. Sandweg has 25 years of sales, sales training, and sales management experience. During the past 19 years, he has held roles of increasing responsibility within the cardiovascular and structural heart space for Boston Scientific, Medtronic, and Direct Flow Medical. While with Medtronic, he helped to launch several strategic products to include, Endeavor and Resolute, the companies first drug eluting stents. He also served on the original US Sales Management Team responsible for launching CoreValve and CoreValve EVOLUT, the companies first transcatheter

Dr. Nitzan has more than 15 years of experience in the field of medical devices, serving in various cardiac valve devices. Prior to joining Keystone Heart, Mr. Sandweg served as the Director of US positions including R&D, application manager, quality assurance, clinical studies and regulatory field Operations for Direct Flow Medical and was responsible for all field operations supporting affairs. Prior to joining Keystone Heart, Dr. Nitzan served as Global Director of Clinical and Regulatory Affairs at Given Imaging Ltd, managing clinical studies world-wide.

## Board of Directors

### Vince Burgess

Executive Chairman

Mr. Burgess is a venture partner at OrbiMed Advisors LLC with over 20 years of experience in healthcare operations, business development and venture capital. Vince was on the founding executive team at Volcano Corp., serving as group president, advanced imaging systems. Previously, Mr. Burgess served as a general partner of San Diego-based Sorrento Ventures, focusing on healthcare investments.

### Nissim Darvish, M.D., Ph.D.

Director

Dr. Darvish is a senior managing director at OrbiMed. He has more than 15 years of experience in the life science industry, covering medical technology development, corporate leadership and investment management. Dr. Darvish spent eight years with Pitango, where he was a general partner managing life science investments. Previously, he was the founder and CEO of Impulse Dynamics.

### Mark Maciejewski

Director

Mr. Maciejewski is experienced in venture capital and private equity funding within the global life science company relationships, with specialization in joint venture formation and transactions. With broad operational expertise, Mr. Maciejewski has held several CEO-level executive positions with large multi-national device firms and small venture backed start-ups, founded, formed and funded numerous early-stage companies including: AngioGuard, Devax, Symphony Medical, Suturtek, Celleration, RegenRx and Venus MedTech. He has also assumed responsibilities for "cross border transactions" between China (listed and private PRC companies) and US entities.

### David P. Bonita, M.D.

Director

Dr. Bonita is a private equity partner at OrbiMed Advisors LLC. Prior to joining OrbiMed, Dr. Bonita worked as a corporate finance analyst in the healthcare investment banking groups of Morgan Stanley and UBS. He has also published scientific articles in peer reviewed journals based on clinical transduction research performed at the Harvard Medical School.

### Chris Richardson

Director

Mr. Richardson has spent his 25-year career taking cardiac startup companies from the clinical trial phase through worldwide commercialization and into acquisition. Prior to joining Keystone Heart, Mr. Richardson was international president and CCO of Direct Flow Medical, a transcatheter aortic valve company, and general manager of Abbott Vascular Structural Heart, a percutaneous mitral valve repair, which he joined through its acquisition of Evalve. Mr. Richardson has also held leadership positions at Boston Scientific's Cardiac Rhythm Management business and GSC Management Development at Guidant, Heartport (acquired by Johnson & Johnson) and Devices for Vascular Intervention (acquired by Guidant).

### Jack B. Yang

Director

Mr. Yang is Founding Partner of Ming Capital (focused on global medical devices VC investment) with over 25 years of M&As or investment experience, and serves on the board of a European cardiovascular company and its Remuneration Committee. He was Investment Committee member of New Hope Industry Fund I (USD) and successfully managed high-tech funds covering medical devices in China. Prior to that, he worked mainly with Rothschild Investment banking in London and Hong Kong, doing M&As in Europe and East & Southeast Asia, respectively. He also worked with CITIC Group in Beijing and Tokyo.

### Disclaimer

CAUTION - The TriGUARD™ Cerebral Embolic Protection Device is not commercially available. An investigational device for investigational use only.

"TRIGUARD Cerebral Embolic Protection Device" and TriGUARD3™ Cerebral Embolic Protection Device are trademarks owned by Keystone Heart, LTD, and may be registered. All other trademarks are the property of their respective owners.

### Contact Us

15 Halamish St., PO 3170, Caesarea, 3089900

T | +972.4.615.8000 | +972.4.615.8099

3000 Bayport Drive, Suite 980 Tampa, FL 33607

Tampa (813) 530-8200

info@keystoneheart.com

### Latest News

[Watch] Keystone Heart Interview on Worldwide with Kathy Ireland

VIEW ...

March 22, 2017

Are We Under-Reporting Stroke Rates In TAVR Studies?

In Honor of National Stroke ...

May 9, 2018

Cerebral Embolic Protection Panel Discussion

Alexandra Lansky Patient ...

December 3, 2018

### Sitemap

Who We Are

Clinical Evidence

Clinical Studies

Abstracts | Manuscripts

Presentations

Technology

Latest News

News

Press Release

Events

Contact us

WATCH EUROPCR 2019 SYMPOSIUM



Copyright Keystone Heart 2019. All Rights Reserved.